Latest

Jan 04, 2017
Connected ecosystems will change the future of healthcare. William King outlines three key value drivers.
Dec 12, 2016
Pharmaceutical Executive
How a Manufacturing Excellence program can deliver competitive advantage to a fast-changing global product mix—at lower cost, and with an unexpected workforce dividend to boot.
Dec 08, 2016
Uncertainty surrounds the future of drug pricing reform, causing industry observers to take a closer look at the policy views of the president-elect, state and Congressional lawmakers, and the general public.
Dec 08, 2016
It's time to take advantage of a nascent technology embrace taking hold among market insights professionals, writes Janet Kolsoff.
Nov 30, 2016
How the need for biopharma innovation extends to questions around executive compensation. By Carl Sjostrom and Ian Wilcox
Nov 29, 2016
Biosimilars are gaining more support among payers and physicians, but more needs to be done to explain their benefits as well as their safety and efficacy profiles, writes Barbara Testa.
Nov 29, 2016
However conservative and heavily regulated the drugs business, it too must transform itself to exploit digital opportunities — if only to ward off disruption, says Elvis Paćelat.
Nov 22, 2016
“Volume is not a dirty word” was outgoing GSK head Sir Andrew Witty’s key message at this month's FT Global Pharmaceutical Conference in London.
Nov 18, 2016
Biopharma companies should no longer consider FDA an obstacle to innovation and in need of major reform, according to Jim Greenwood, President of BIO.
Nov 11, 2016
Pharmaceutical Executive
An industry-based working group presents a common standards and definition framework for “Access” competencies in pharma.
native1_300x100
lorem ipsum